| Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (NCT05182164) | Institut Bergonié | 2022-04-25 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma (NCT05116800) | Brown University | 2022-03-01 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas (NCT04906876) | Brown University | 2021-09-01 |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients (NCT05961761) | Niels Junker | 2021-08-17 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (NCT04480502) | Tracon Pharmaceuticals Inc. | 2020-12-09 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (NCT04420975) | Jonsson Comprehensive Cancer Center | 2020-10-14 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg (NCT04332874) | Memorial Sloan Kettering Cancer Center | 2020-04-01 |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (NCT04055220) | Centre Leon Berard | 2020-03-03 |
| Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma (NCT04123535) | Matthew Bucknor | 2020-01-23 |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (NCT04242238) | Memorial Sloan Kettering Cancer Center | 2020-01-22 |
| Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients (NCT04008238) | Institut Bergonié | 2020-01-06 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (NCT02923778) | National Cancer Institute (NCI) | 2019-12-31 |
| A Study of LY3435151 in Participants With Solid Tumors (NCT04099277) | Eli Lilly and Company | 2019-10-28 |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma (NCT03946943) | Di Wu | 2019-07-19 |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (NCT03899805) | Dana-Farber Cancer Institute | 2019-06-04 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (NCT03752398) | Xencor, Inc. | 2019-05-01 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas (NCT03989596) | Maria Sklodowska-Curie National Research Institute of Oncology | 2018-06-01 |
| Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery (NCT03307616) | M.D. Anderson Cancer Center | 2017-10-04 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall (NCT03651375) | Maria Sklodowska-Curie National Research Institute of Oncology | 2017-02-11 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma (NCT02584309) | Washington University School of Medicine | 2016-02-22 |
| ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors (NCT02565758) | AbbVie | 2015-09-18 |